Kitsune Biotherapeutics
The University of Colorado Connection
Kitsune Bio is a Boulder-based biotechnology startup developing shape-shifting cyclic peptides (SSCPs) that adapt their structure to access and modulate challenging intracellular targets. The company was founded through the CU Boulder Embark Deep Tech Startup Creator, pairing entrepreneurs Makenna Morck and Alec Santiago with technology developed by Michael Stowell (CU Boulder Molecular, Cellular & Developmental Biology). Kitsune’s platform enables peptides to cycle through over 1,000 structural isomers, enhancing their ability to penetrate cells and bind to dynamic, previously “undruggable” proteins. The company is currently focused on internal asset optimization and is open to collaborations, licensing and strategic partnerships in the cyclic peptide space.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: Makenna Morck , makenna@kitsunebio.com and Alec Santiago , alec@kitsunebio.com
In the News
- University of Colorado's Ascent Deep Tech Accelerator to showcase 2025 cohort in June (2025)
- Congratulations to our NVC Specialty Competition winners! (2025)
- CU Boulder hosts showcases highlighting breakthrough innovations and investment-ready ventures (2025)
- 2024 cohort of CU Boulder’s Embark Deep Tech Startup Creator launches new startups (2024)
- $1.25M awarded to University of Colorado innovators to advance their discoveries (2024)
Venture Partners Programs
This page was last updated on May 19, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.